Gefitinib, EGFR tyrosine kinase inhibitor (ab142052)
Key features and details
- Orally active, potent, selective EGFR tyrosine kinase inhibitor
- CAS Number: 184475-35-2
- Purity: > 98%
- Soluble in DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
Gefitinib, EGFR tyrosine kinase inhibitor -
Description
Orally active, potent, selective EGFR tyrosine kinase inhibitor -
Alternative names
- Iressa™
- ZD 1839
- ZD1839
-
Biological description
Orally active, potent, selective EGFR (Epidermal growth factor receptor) tyrosine kinase inhibitor (IC50 = 33 nM). Inhibits EGF-stimulated EGFR autophosphorylation and inhibits tumor growth in vivo. Enhances efficacy of cytotoxic agents. Inhibits growth factor production and angiogenesis. Clinically useful anticancer agent.
-
Purity
> 98% -
CAS Number
184475-35-2 -
Chemical structure
Properties
-
Chemical name
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine -
Molecular weight
446.90 -
Molecular formula
C22H24ClFN4O3 -
PubChem identifier
123631 -
Storage instructions
Shipped at Room Temperature. Store at -20°C. Store under desiccating conditions. -
Solubility overview
Soluble in DMSO to 100 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4 -
Source
Synthetic
-
Research areas
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (3)
ab142052 has been referenced in 3 publications.
- Gan CJ et al. EGF receptor inhibitors comprehensively suppress hepatitis B virus by downregulation of STAT3 phosphorylation. Biochem Biophys Rep 22:100763 (2020). PubMed: 32322693
- Yan J et al. GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma. Am J Cancer Res 10:3705-3720 (2020). PubMed: 33294262
- Devaraj V & Bose B Morphological State Transition Dynamics in EGF-Induced Epithelial to Mesenchymal Transition. J Clin Med 8:N/A (2019). PubMed: 31247884